Skip to search formSkip to main contentSkip to account menu

Selective Estrogen Receptor Degrader/Modulator RAD1901

Known as: RAD1901, SERD/SERM RAD1901 
An orally available, selective estrogen receptor degrader (SERD) and selective estrogen receptor modulator (SERM), with potential antineoplastic and… 
National Institutes of Health

Related topics

Related topics

1 relation
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Abstract P4-13-03: Elacestrant (RAD1901) demonstrates anti-tumor activity in models resistant to CDK4/6 inhibitors
2018
2018
Abstract P4-04-09: New oral SERD elacestrant (RAD1901) shows efficacy in breast cancer models harbouring ESR1 mutations and enhances the antiproliferative activity of mTORC1 and CDK4/6 inhibitors
Background: Targeting estrogen receptor (ER) signalling is the main therapeutic option for ER+ breast cancer (BC). However, over… 
2018
2018
Abstract P4-04-17: Elacestrant (RAD1901) demonstrates anti-tumor activity in a fulvestrant-resistant PDX model
Background: Breast cancer is subdivided into categories based on tumor receptor status, with estrogen-receptor positive (ER… 
2018
2018
Abstract P1-10-04: Elacestrant, a novel oral selective estrogen receptor degrader (SERD), decreases tumoral 18F-FES uptake in a phase 1 study of ER+, HER2 -, advanced breast cancer patients
Background: The estrogen receptor (ER) expressed in approximately 70% of breast cancers, can be mapped using 16α-[18F]Fluoro-17… 
2017
2017
Abstract P3-04-22: RAD1901 demonstrates anti-tumor activity in multiple models of ER-positive breast cancer treatment resistance
2017
2017
Abstract 4160: Impact of oral selective estrogen receptor degrader RAD1901 in preclinical models of endocrine sensitive/resistant breast cancer
2016
2016
A phase 1 dose escalation study of RAD1901, an oral selective estrogen receptor degrader, in healthy postmenopausal women
Estrogen and the estrogen receptor (ER) are known to be prominent drivers of breast tumourigenesis and breast cancer progression… 
2016
2016
Abstract P3-05-07: RAD1901, a novel oral, selective estrogen receptor degrader (SERD) with single agent efficacy in an ER+ primary patent derived ESR1 mutant xenograft model
Despite advances in the treatment of metastatic breast cancer, many women eventually relapse with more aggressive forms of… 
2016
2016
Abstract OT2-01-10: A phase 1 study of RAD1901, a novel, orally available, selective estrogen receptor degrader, for the treatment of ER positive advanced breast cancer
The current NCCN treatment guidelines for ER+ breast cancer involves the use of approved agents such as fulvestrant, tamoxifen… 
2015
2015
A phase I study of RAD1901, an oral selective estrogen receptor degrader, in ER–positive, HER2–negative, postmenopausal advanced breast cancer patients.
TPS638 Background: RAD1901 is a novel, non-steroidal, orally bioavailable selective estrogen receptor degrader (SERD… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)